| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.52 [0.29, 0.94] | | < 1 | | 85% | 3 studies (3/-) | 98.5 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.46 [0.36, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.42 [0.33, 0.53] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.53 [0.35, 0.79] | | < 1 | | 89% | 3 studies (3/-) | 99.9 % | low | not evaluable | high | important | - |
| DOR (extension) | 3.45 [1.46, 8.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.66 [1.12, 6.34] | | > 1 | | 92% | 3 studies (3/-) | 98.7 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 4.50 [2.79, 7.25] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.78 [0.34, 1.76] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.84 [0.56, 1.25] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.21 [0.43, 3.38] | | < 1 | | 0% | 2 studies (2/-) | 35.7 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.69 [0.46, 1.04] | | < 1 | | 0% | 2 studies (2/-) | 96.4 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.61 [0.29, 1.28] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.73 [0.49, 1.10] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.74 [0.47, 1.17] | | < 1 | | 0% | 1 study (1/-) | 90.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.20 [0.86, 1.66] | | < 1 | | 0% | 2 studies (2/-) | 14.4 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 0.99 [0.44, 2.27] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.93 [0.60, 1.43] | | < 1 | | 0% | 2 studies (2/-) | 63.7 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.95 [0.43, 2.13] | | < 1 | | 81% | 2 studies (2/-) | 54.6 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.40 [0.48, 4.06] | | < 1 | | 0% | 2 studies (2/-) | 26.8 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.79 [0.39, 8.22] | | < 1 | | 0% | 2 studies (2/-) | 22.8 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.48 [0.04, 5.47] | | < 1 | | 0% | 2 studies (2/-) | 72.1 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.69 [0.24, 2.02] | | < 1 | | 0% | 2 studies (2/-) | 74.9 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 2.66 [0.23, 30.36] | | < 1 | | 0% | 2 studies (2/-) | 21.7 % | low | not evaluable | high | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.19 [0.09, 16.28] | | < 1 | | 47% | 2 studies (2/-) | 45.0 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 3.26 [0.33, 32.32] | | < 1 | | 0% | 2 studies (2/-) | 15.8 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.00 [0.06, 16.02] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.00 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.12 [0.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 91.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.37 [0.79, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 13.0 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.92 [0.25, 14.93] | | < 1 | | 0% | 2 studies (2/-) | 26.8 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.25 [0.04, 1.62] | | < 1 | | 0% | 2 studies (2/-) | 92.6 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.29] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.29 [0.32, 16.34] | | < 1 | | 0% | 2 studies (2/-) | 20.5 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.04 [0.24, 4.45] | | < 1 | | 0% | 2 studies (2/-) | 48.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.00 [0.54, 1.83] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.05 [0.00, 0.82] | | < 1 | | 0% | 1 study (1/-) | 98.1 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.58 [0.14, 2.41] | | < 1 | | 0% | 2 studies (2/-) | 77.1 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
